

CALCIUM POLYSTYRENE SULFONATE

Effective and safe treatment option in the management of Hyperkalaemia



General Information

Name:	Resincalcio®
API:	Calcium Polystyrene Sulphonate
Presentation:	15 g x 26 sachets 400 g multi-dose plastic bottle with a measuring spoon that holds approx. 5 g
Pharmaceutical form:	Powder for oral/rectal suspension

Indications

- Treatment of hyperkalaemia in adults and children.

Competitives Advantages

- Resincalcio® has showed efficacy in the reduction of potassium.
- Resincalcio® is indicated for patients treated with dialysis with hyperkalaemia.
- With sugar free.
- Non-systemic absorption.
- Low cost in daily treatment.

Clinical Studies

- Clinical bibliographical data available for the active substance.

Registration and Marketing Authorization

- Bibliographical dossier available (well-established medical use).
- Resincalcio® is marketed in Spain since 1968.
- To be registered as well established medicinal use drug: The originator is Calcium Resonium® / Kayexalate Calcium®. Calcium polystyrene sulphonate is an insoluble, locally acting, with no systemic absorption substance. The bioequivalence study is not a suitable way to show therapeutic equivalence for this type of products. Bridging to data on formulations described in literature should be justified based on qualitative and quantitative composition. In some particular cases, an "in vitro" study of Resincalcio® against the originator or the reference product in the country is required.
- Marketed in CL, CO, CU, DO, GT, HN, HR, KW, MA, MX, MY, NI, PH, PK, SA, SG, SV, TH, UK and VN. Under registration process in DE.

Deal Design

- We are looking for partners having a relevant sales structure in Nephrology, specially oriented to Hospitals, Clinics, Dialysis Centres and Nephrologists.
- Deal design consisting of a Supply & Distribution and/or Licensing and Supply Agreement to market the Finished Product manufactured by Laboratorios Rubió, S.A.
- We are searching for the best Partners to develop trustful, fruitful and long term business partnerships.



Rubió 55

We are pharmacypathfinders

Founded

1968

Location

Castellbisbal, Barcelona, Spain

Main Focus

CNS, Nephrology/Urology, Cardiovascular, Gastroenterology, Rheumatology/Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubió

For 55 years Laboratorios Rubió, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Laboratorios Rubió's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partnering Strategy

Laboratorios Rubió has established a strong network of partnerships through in and out activities and commercial distribution agreements. Laboratorios Rubió has been in the export business since 1982 and has alliances in over 60 countries. Laboratorios Rubió is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubió, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
Fax: +34 937 721 602
www.laboratoriosrubio.com

Contact:

export@labrubio.com